Взаимосвязь экзокринной и эндокринной функций поджелудочной железы в норме и при патологии

В статье рассматриваются теоретические аспекты взаимодействия экзокринной и эндокринной частей поджелудочной железы (ПЖ), а также различные патологии, иллюстрирующие эти процессы. К освещаемым заболеваниям относятся хронический панкреатит (ХП), острый панкреатит (ОП), сахарный диабет (СД), стеатоз ПЖ и некоторые другие. Приведены данные о распространенности СД при различных патологиях ПЖ и о частоте развития экзокринной недостаточности ПЖ (ЭНПЖ) при СД. Представлены факторы риска СД при панкреатической патологии. Обсуждаются механизмы патогенеза упомянутых состояний, рассматриваемые положения подкреплены экспериментальными данными. Кроме того, обсуждаются некоторые потенциальные методы терапевтического воздействия, которые могут повысить эффективность лечения при указанных состояниях.

1. Villaca CBP, Mastracci TL. Pancreatic Crosstalk in the Disease Setting: Understanding the Impact of Exocrine Disease on Endocrine Function. Compr Physiol. 2024; 14 (2): 5371–5387. Published 2024 Mar 29. https://doi.org/10.1002/cphy.c230008

2. Murakami T, Fujita T. Microcirculation of the rat pancreas, with special reference to the insulo-acinar portal and insulo-venous drainage systems: a further scanning electron microscope study of corrosion casts. Arch Histol Cytol. 1992; 55 (5): 453–476. https://doi.org/10.1679/aohc.55.453

3. Murakami T, Hitomi S. et al. Pancreatic insulo-acinar portal systems in humans, rats, and some other mammals: scanning electron microscopy of vascular casts. Microsc Res Tech. 1997; 37 (5–6): 478–488. https://doi.org/10.1002/(SICI)1097–0029(19970601)37:5/6<478::AID-JEMT10>3.0.CO;2-N

4. Pour PM, Standop J, Batra SK. Are islet cells the gatekeepers of the pancreas? Pancreatology. 2002; 2 (5): 440–448. https://doi.org/10.1159/000064718

5. Aughsteen AA, Kataoka K. Morphometric studies on the juxta-insular and tele-insular acinar cells of the pancreas in normal and streptozotocin-induced diabetic rats. J Electron Microsc (Tokyo). 1993; 42 (2): 79–87.

6. Hu C., Chen Y., Yin X. et al. Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status. Sig Transduct Target Ther. 2025; 10: 39. https://doi.org/10.1038/s41392-024-02098-3

7. Schubert ML, Rehfeld JF. Gastric Peptides-Gastrin and Somatostatin. Compr Physiol. 2019; 10 (1): 197–228. Published 2019 Dec 18. https://doi.org/10.1002/cphy.c180035

8. Basile G, Vetere A, Hu J. et al. Excess pancreatic elastase alters acinar-β cell communication by impairing the mechano-signaling and the PAR 2 pathways. Cell Metab. 2023; 35 (7): 1242–1260.e9. https://doi.org/10.1016/j.cmet.2023.05.007

9. Malka D, Hammel P. et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000; 119 (5): 1324–1332. https://doi.org/10.1053/gast.2000.19286

10. Wang W, Guo Y, Liao Z. et al. Occurrence of and risk factors for diabetes mellitus in Chinese patients with chronic pancreatitis. Pancreas. 2011; 40 (2): 206–212. https://doi.org/10.1097/mpa.0b013e31820032ae

11. Zhu X, Liu D, Wei Q. et al. New-Onset Diabetes Mellitus After Chronic Pancreatitis Diagnosis: A Systematic Review and Meta-analysis. Pancreas. 2019; 48 (7): 868–875. https://doi.org/10.1097/MPA.0000000000001359

12. Olesen S. S., Poulsen J. L. et al. Multiple risk factors for diabetes mellitus in patients with chronic pancreatitis: A multicentre study of 1117 cases. United Eur. Gastroenterol. J. 2020; 8: 453–461. https://doi.org/10.1177/2050640620901973

13. Ciochina M., Balaban D. V. et al. The Impact of Pancreatic Exocrine Diseases on the β-Cell and Glucose Metabolism – A Review with Currently Available Evidence. Biomolecules. 2022; 12: 618. https://doi.org/10.3390/biom12050618

14. Talukdar R., Sasikala et al. T-Helper Cell–Mediated Islet Inflammation Contributes to β-Cell Dysfunction in Chronic Pancreatitis. Pancreas. 2016; 45: 434–442. https://doi.org/10.1097/mpa.0000000000000479

15. Sun J, Ni Q. et al. β-Cell Dedifferentiation in Patients With T2D With Adequate Glucose Control and Nondiabetic Chronic Pancreatitis. J Clin Endocrinol Metab. 2019; 104 (1): 83–94. https://doi.org/10.1210/jc.2018-00968

16. Hart PA, Bellin MD. et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016; 1 (3): 226–237. https://doi.org/10.1016/S2468-1253(16)30106-6

17. Kharoud HK, Mettler T. et al. Type 1 diabetes mellitus in patients with recurrent acute and chronic pancreatitis: A case series. Pancreatology. 2021; 21 (1): 95–97. https://doi.org/10.1016/j.pan.2020.12.006

18. Mumme L, Breuer TGK. et al. Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. Diabetes Care. 2017; 40 (10): 1314–1322. https://doi.org/10.2337/dc17-0792

19. Knop FK, Vilsbøll T. et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007; 56 (8): 1951–1959. https://doi.org/10.2337/db07-0100

20. Nagpal SJS, Bamlet WR. et al. Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus. Pancreas. 2018; 47 (6): 738–741. https://doi.org/10.1097/MPA.0000000000001077

21. Seymour NE, Volpert AR. et al. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995; 169 (1): 105–110. https://doi.org/10.1016/s0002-9610(99)80117-2

22. Brunicardi FC, Chaiken RL, Ryan AS. et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996; 81 (10): 3566–3572. https://doi.org/10.1210/jcem.81.10.8855802

23. Yadav D, Whitcomb DC. et al. North American Pancreatitis Studies Consortium. Autoimmunity May Explain Diabetes in a Subset of Patients With Recurrent Acute and Chronic Pancreatitis: A Pilot Study. Clin Gastroenterol Hepatol. 2023; 21 (1): 226–228.e1. https://doi.org/10.1016/j.cgh.2021.11.011

24. Woodmansey C, McGovern AP. et al. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care. 2017; 40 (11): 1486–1493. https://doi.org/10.2337/dc17-0542

25. Zhi M, Zhu X. et al. Incidence of New Onset Diabetes Mellitus Secondary to Acute Pancreatitis: A Systematic Review and Meta-Analysis. Front Physiol. 2019; 10: 637. Published 2019 May 31. https://doi.org/10.3389/fphys.2019.00637

26. Bharmal SH, Cho J. et al. Trajectories of glycaemia following acute pancreatitis: a prospective longitudinal cohort study with 24 months follow-up. J Gastroenterol. 2020; 55 (8): 775–788. https://doi.org/10.1007/s00535-020-01682-y

27. Lee YK, Huang MY, Hsu CY, Su YC. Bidirectional Relationship Between Diabetes and Acute Pancreatitis: A Population-Based Cohort Study in Taiwan. Medicine (Baltimore). 2016; 95 (2): e2448. https://doi.org/10.1097/MD.0000000000002448

28. Das SL, Singh PP. et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014; 63 (5): 818–831. https://doi.org/10.1136/gutjnl-2013-305062

29. Zahariev OJ, Bunduc S. et al. Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Front Med (Lausanne). 2024; 10: 1257222. Published 2024 Jan 9. https://doi.org/10.3389/fmed.2023.1257222

30. Cho J, Scragg R. et al. Exocrine Pancreatic Dysfunction Increases the Risk of New-Onset Diabetes Mellitus: Results of a Nationwide Cohort Study. Clin Transl Sci. 2021; 14 (1): 170–178. https://doi.org/10.1111/cts.12837

31. Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne). 2023; 14: 1239335. Published 2023 Sep 19. https://doi.org/10.3389/fendo.2023.1239335

32. Tu J, Yang Y, Zhang J. et al. Effect of the disease severity on the risk of developing new-onset diabetes after acute pancreatitis. Medicine (Baltimore). 2018; 97 (22): e10713. https://doi.org/10.1097/MD.0000000000010713.

33. Petrov MS. Panorama of mediators in postpancreatitis diabetes mellitus. Curr Opin Gastroenterol. 2020; 36 (5): 443–451. https://doi.org/10.1097/MOG.0000000000000654

34. Pichardo-Lowden A, Goodarzi MO. et al. Risk and factors determining diabetes after mild, nonnecrotizing acute pancreatitis. Curr Opin Gastroenterol. 2024; 40 (5): 396–403. https://doi.org/10.1097/MOG.0000000000001055

35. Zhang C, Li G. et al. The Interaction of Microbiome and Pancreas in Acute Pancreatitis. Biomolecules. 2023; 14 (1): 59. Published 2023 Dec 31. https://doi.org/10.3390/biom14010059

36. Rosendo-Silva D, Viana S. et al. Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved. Intern Emerg Med. 2023; 18 (5): 1287–1302. https://doi.org/10.1007/s11739-023-03262-3

37. Kimita W, Bharmal SH, Ko J, Petrov MS. Identifying endotypes of individuals after an attack of pancreatitis based on unsupervised machine learning of multiplex cytokine profiles. Transl Res. 2023; 251: 54–62. https://doi.org/10.1016/j.trsl.2022.07.001.

38. Al-Ani Z, Ko J, Petrov MS. Intra-pancreatic fat deposition across the pancreatitis spectrum and the influence of gut hormones. Dig Liver Dis. 2023; 55 (8): 1081–1090. https://doi.org/10.1016/j.dld.2023.02.013

39. Lv Y, Lu X, Liu G. et al. Differential Diagnosis of Post Pancreatitis Diabetes Mellitus Based on Pancreatic and Gut Hormone Characteristics. J Clin Endocrinol Metab. 2024; 109 (8): 2003–2011. https://doi.org/10.1210/clinem/dgae080

40. Chen W, Binbin G. et al. Evolution of peptide YY analogs for the management of type 2 diabetes and obesity. Bioorg Chem. 2023; 140: 106808. https://doi.org/10.1016/j.bioorg.2023.106808

41. Larger E, Philippe MF. et al. Pancreatic exocrine function in patients with diabetes. Diabet Med. 2012; 29 (8): 1047–1054. https://doi.org/10.1111/j.1464-5491.2012.03597.x

42. Frier BM, Saunders JH, Wormsley KG, Bouchier IA. Exocrine pancreatic function in juvenile-onset diabetes mellitus. Gut. 1976; 17 (9): 685–691. https://doi.org/10.1136/gut.17.9.685

43. Ferrer R, Medrano J. et al. Effect of exogenous insulin and glucagon on exocrine pancreatic secretion in rats in vivo. Int J Pancreatol. 2000; 28 (1): 67–75. https://doi.org/10.1385/IJGC:28:1:67.

44. Radlinger B, Ramoser G, Kaser S. Exocrine Pancreatic Insufficiency in Type 1 and Type 2 Diabetes. Curr Diab Rep. 2020; 20 (6): 18. Published 2020 Apr 1. https://doi.org/10.1007/s11892-020-01304-0

45. Kunovský L, Dítě P. et al. Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis. J Clin Med. 2021; 10 (24): 5779. Published 2021 Dec 10. https://doi.org/10.3390/jcm10245779

46. Wright JJ, Eskaros A. et al. Exocrine Pancreas in Type 1 and Type 2 Diabetes: Different Patterns of Fibrosis, Metaplasia, Angiopathy, and Adiposity. Diabetes. 2024; 73 (7): 1140–1152. https://doi.org/10.2337/db23-0009

47. Yagihashi S. Diabetes and pancreas size, does it matter? J Diabetes Investig. 2017; 8 (4): 413–415. https://doi.org/10.1111/jdi.12590

48. Zhang AMY, Xia YH. et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metab. 2023; 35 (12): 2119–2135.e5. https://doi.org/10.1016/j.cmet.2023.10.003

49. Pieńkowska J, Brzeska B. et al. MRI assessment of ectopic fat accumulation in pancreas, liver and skeletal muscle in patients with obesity, overweight and normal BMI in correlation with the presence of central obesity and metabolic syndrome. Diabetes Metab Syndr Obes. 2019; 12: 623–636. Published 2019 May 3. https://doi.org/10.2147/DMSO.S194690

50. Abdullah A, Peeters A. et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010; 89 (3): 309–319. https://doi.org/10.1016/j.diabres.2010.04.012

51. Lu T, Wang Y. et al. Pancreatic fat content is associated with β-cell function and insulin resistance in Chinese type 2 diabetes subjects. Endocr J. 2019; 66 (3): 265–270. https://doi.org/10.1507/endocrj.EJ18-0436

52. Altinmakas E, Guler B. et al. Determinants of Pancreatic Steatosis: A Retrospective Observational Study. Middle East J Dig Dis. 2021; 13 (4): 343–349. https://doi.org/10.34172/mejdd.2021.245

53. Wang X, Misawa R. et al. Regional differences in islet distribution in the human pancreas – preferential beta-cell loss in the head region in patients with type 2 diabetes. PLoS One. 2013; 8 (6): e67454. Published 2013 Jun 24. https://doi.org/10.1371/journal.pone.0067454

54. Miyake H, Sakagami J. et al. Association of fatty pancreas with pancreatic endocrine and exocrine function. PLoS One. 2018; 13 (12): e0209448. Published 2018 Dec 20. https://doi.org/10.1371/journal.pone.0209448

55. Tahtacı M, Algın O. et al. Can pancreatic steatosis affect exocrine functions of pancreas? Turk J Gastroenterol. 2018; 29 (5): 588–594. https://doi.org/10.5152/tjg.2018.17696

56. Skudder-Hill L, Sequeira IR. et al. Fat Distribution Within the Pancreas According to Diabetes Status and Insulin Traits. Diabetes. 2022; 71 (6): 1182–1192. https://doi.org/10.2337/db21-0976

57. LJ de O Andrade, GC M de Oliveira. et al. Is Non-Alcoholic Fatty Pancreatic Disease a Mechanism of Beta-cells Dedifferentiation to Trigger Type 2 Diabetes Mellitus? 27 July 2021, PREPRINT (Version 1) available at Research Square. https://doi.org/10.21203/rs.3.rs-753823/v1

58. Mathur A, Marine M. et al. Nonalcoholic fatty pancreas disease. HPB (Oxford). 2007; 9 (4): 312–318. https://doi.org/10.1080/13651820701504157

59. Gerst F, Wagner R. et al. What role do fat cells play in pancreatic tissue? Mol Metab. 2019; 25: 1–10. https://doi.org/10.1016/j.molmet.2019.05.001

60. Wagner R, Eckstein SS. et al. Metabolic implications of pancreatic fat accumulation. Nat Rev Endocrinol. 2022; 18 (1): 43–54. https://doi.org/10.1038/s41574-021-00573-3

61. Panchoo AV, VanNess GH. et al. Hereditary pancreatitis: An updated review in pediatrics. World J Clin Pediatr. 2022; 11 (1): 27–37. Published 2022 Jan 9. https://doi.org/10.5409/wjcp.v11.i1.27

62. Rebours V, Boutron-Ruault MC. et al. The natural history of hereditary pancreatitis: a national series. Gut. 2009; 58 (1): 97–103. https://doi.org/10.1136/gut.2008.149179

63. Howes N, Lerch MM. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004; 2 (3): 252–261. https://doi.org/10.1016/s1542–3565(04)00013-8

64. El Jellas K, Dušátková P. et al. Two New Mutations in the CEL Gene Causing Diabetes and Hereditary Pancreatitis: How to Correctly Identify MODY 8 Cases. J Clin Endocrinol Metab. 2022; 107 (4): e1455–e1466. https://doi.org/10.1210/clinem/dgab864

65. Ramalho GX, Dytz MG. Diabetes of the Exocrine Pancreas Related to Hereditary Pancreatitis, an Update. Curr Diab Rep. 2020; 20 (6): 16. Published 2020 Mar 28. https://doi.org/10.1007/s11892-020-01299-8

66. Dytz MG, Marcelino PA. et al. Clinical aspects of pancreatogenic diabetes secondary to hereditary pancreatitis. Diabetol Metab Syndr. 2017; 9: 4. Published 2017 Jan 13. https://doi.org/10.1186/s13098-017-0203-7

67. Whitcomb DC, Gorry MC. et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996; 14 (2): 141–145. https://doi.org/10.1038/ng1096–141

68. Felicelli C, Pezhouh MK. Histopathology of SPINK-1 Hereditary Pancreatitis. Int J Surg Pathol. 2021; 29 (5): 529–533. https://doi.org/10.1177/1066896920980086

69. Archer H, Jura N. et al. A mouse model of hereditary pancreatitis generated by transgenic expression of R 122H trypsinogen. Gastroenterology. 2006; 131 (6): 1844–1855. https://doi.org/10.1053/j.gastro.2006.09.049

70. Raeder H, Johansson S, Holm PI. et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006; 38 (1): 54–62. https://doi.org/10.1038/ng1708

71. Durie PR, Forstner GG. Pathophysiology of the exocrine pancreas in cystic fibrosis. J R Soc Med. 1989; 82 (Suppl 16): 2–10.

72. Moran A, Dunitz J. et al. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32 (9): 1626–1631. https://doi.org/10.2337/dc09-0586

73. Blackman SM, Hsu S. et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia. 2009; 52 (9): 1858–1865. https://doi.org/10.1007/s00125-009-1436-2

74. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013; 12 (4): 318–331. https://doi.org/10.1016/j.jcf.2013.02.008

75. O’Malley Y, Coleman MC. et al. Oxidative stress and impaired insulin secretion in cystic fibrosis pig pancreas. Adv Redox Res. 2022; 5: 100040. https://doi.org/10.1016/j.arres.2022.100040

76. Hasan S, Soltman S. et al. The role of genetic modifiers, inflammation and CFTR in the pathogenesis of Cystic fibrosis related diabetes. J Clin Transl Endocrinol. 2021; 27: 100287. Published 2021 Dec 10. https://doi.org/10.1016/j.jcte.2021.100287

77. Hull RL, Gibson RL. et al. Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure. Diabetes Care. 2018; 41 (4): 823–830. https://doi.org/10.2337/dc17-1387

78. Löhr M, Goertchen P. et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Arch A Pathol Anat Histopathol. 1989; 414 (2): 179–185. https://doi.org/10.1007/BF00718598

79. Bogdani M, Blackman SM. et al. Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes. Sci Rep. 2017; 7 (1): 17231. Published 2017 Dec 8. https://doi.org/10.1038/s41598–017-17404-z

80. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71 (1): 7–33. https://doi.org/10.3322/caac.21654

81. Pannala R, Leirness JB. et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008; 134 (4): 981–987. https://doi.org/10.1053/j gastro.2008.01.039

82. Sah RP, Nagpal SJ. et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013; 10 (7): 423–433. https://doi.org/10.1038/nrgastro.2013.49

83. Chari ST, Andersen DK. Metabolic Surveillance for Those at High Risk for Developing Pancreatic Cancer. Gastroenterology. 2021; 161 (5): 1379–1380. https://doi.org/10.1053/j.gastro.2021.07.006

84. Salvatore T, Marfella R. et al. Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surg. 2015; 21 Suppl 1: S 72–S 77. https://doi.org/10.1016/j.ijsu.2015.06.063

85. Nagpal SJS, Kandlakunta H. et al. Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitus. Pancreatology. 2020; 20 (5): 929–935. https://doi.org/10.1016/j.pan.2020.05.010

86. Nunemaker CS. Considerations for Defining Cytokine Dose, Duration, and Milieu That Are Appropriate for Modeling Chronic Low-Grade Inflammation in Type 2 Diabetes. J Diabetes Res. 2016; 2016: 2846570. https://doi.org/10.1155/2016/2846570

87. Wang Y, Ni Q, Sun J. et al. Paraneoplastic β Cell Dedifferentiation in Nondiabetic Patients with Pancreatic Cancer. J Clin Endocrinol Metab. 2020; 105 (4): dgz224. https://doi.org/10.1210/clinem/dgz224

88. Gao W, Zhou Y, Li Q. et al. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma. Diabetologia. 2015; 58 (4): 835–844. https://doi.org/10.1007/s00125-014-3481-8

89. Javeed N, Sagar G. et al. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction. Clin Cancer Res. 2015; 21 (7): 1722–1733. https://doi.org/10.1158/1078–0432.CCR-14-2022

90. King J, Kazanjian K. et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg. 2008; 12 (9): 1548–1553. https://doi.org/10.1007/s11605-008-0560-5

91. Beger HG, Mayer B, Poch B. Resection of the duodenum causes long-term endocrine and exocrine dysfunction after Whipple procedure for benign tumors – Results of a systematic review and meta-analysis. HPB (Oxford). 2020; 22 (6): 809–820. https://doi.org/doi:10.1016/j.hpb.2019.12.016

92. Singh AN, Pal S. et al. Diabetes after pancreaticoduodenectomy: can we predict it? J Surg Res. 2018; 227: 211–219. https://doi.org/10.1016/j.jss.2018.02.010

93. Shibata S, Sato T. et al. Outcomes and indications of segmental pancreatectomy. Comparison with distal pancreatectomy. Dig Surg. 2004; 21 (1): 48–53. https://doi.org/doi:10.1159/000075826

94. Schrader H, Menge BA. et al. Determinants of glucose control in patients with chronic pancreatitis. Diabetologia. 2010; 53 (6): 1062–1069. https://doi.org/10.1007/s00125-010-1705-0

95. Menge BA, Breuer TG. et al. Long-term recovery of β-cell function after partial pancreatectomy in humans. Metabolism. 2012; 61 (5): 620–624. https://doi.org/10.1016/j.metabol.2011.09.019

96. Sohn SY, Lee EK. et al. Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer. Medicine (Baltimore). 2018; 97 (18): e0590. https://doi.org/10.1097/MD.0000000000010590

97. Moggia E, Koti R. et al. Pharmacological interventions for acute pancreatitis. Cochrane Database Syst Rev. 2017; 4 (4): CD 011384. Published 2017 Apr 21. https://doi.org/10.1002/14651858.CD011384.pub2

98. IAP/APA/EPC/IPC/JPS Working Group. Electronic address: info@internationalpancreatology. org; IAP/APA/EPC/IPC/JPS Working Group. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society. Pancreatology. 2025; 25 (6): 770–814. https://doi.org/10.1016/j.pan.2025.04.020

99. Ивашкин В. Т., Кригер А. Г. и др. Клинические рекомендации по диагностике и лечению хронического панкреатита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32 (2): 99–156. https://doi.org/10.22416/1382-4376-2022-32-2-99-156. I

100. Затевахин И. И., Ревишвили А. Ш. и др. Острый панкреатит. Клинические рекомендации МЗ РФ 2024. https://cr.minzdrav.gov.ru/view-cr/903_1

101. Kothegala L, Miranda C. et al. Somatostatin Containing δ-Cell Number Is Reduced in Type-2 Diabetes. Int J Mol Sci. 2023; 24 (4): 3449. Published 2023 Feb 9. https://doi.org/10.3390/ijms24043449

102. Boehm BO. The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. Expert Opin Investig Drugs. 2003; 12 (9): 1501–1509. https://doi.org/10.1517/13543784.12.9.1501

103. Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci. 2020; 21 (5): 1682. Published 2020 Feb 29. https://doi.org/10.3390/ijms21051682

104. Davies RR, Turner SJ. et al. Somatostatin analogues in diabetes mellitus. Diabet Med. 1989; 6 (2): 103–111. https://doi.org/10.1111/j.1464–5491.1989.tb02096.x

105. Rickels MR, Bellin M. et al. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013; 13 (4): 336–342. https://doi.org/10.1016/j.pan.2013.05.002

106. Cho J, Scragg R. et al. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study. Diabetes Care. 2019; 42 (9): 1675–1683. https://doi.org/10.2337/dc19-0145

107. Wang Z, Lai ST, Xie L. et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014; 106 (1): 19–26. https://doi.org/10.1016/j.diabres.2014.04.007

108. Багрий А. Э., Щукина Е. В. и др. Возможности применения метформина у больных с сахарным диабетом, развившимся на фоне панкреатита. Университетская клиника. 2022; 4 (45): 5–11.

109. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012; 13 (12): 1797–1805. https://doi.org/10.1517/14656566.2012.705829

110. Marso SP, Daniels GH. et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375 (4): 311–322. https://doi.org/10.1056/NEJMoa1603827

111. Elashoff M, Matveyenko AV. et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141 (1): 150–156. https://doi.org/10.1053/j.gastro.2011.02.018.

112. Singh A, Aggarwal M. et al. Post-pancreatitis diabetes mellitus: insight on optimal management with nutrition and lifestyle approaches. Ann Med. 2022; 54 (1): 1776–1786. https://doi.org/10.1080/07853890.2022.2090601